Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 10/20 | 0.54 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSK | P43235 | 1/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.49 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.49 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.49 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.49 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.49 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.49 |
| ▸ | REN | P00797 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23331375 | 1.00 | CTSD (0.54) | CTSDBACE1BACE2KISS1RCTSB | |
| SCHEMBL23331574 | 0.93 | CTSD (0.55) | CTSDBACE1BACE2KISS1R | |
| SCHEMBL23331572 | 0.93 | CTSD (0.55) | CTSDBACE1BACE2KISS1R | |
| SCHEMBL23331377 | 0.91 | KISS1R (0.57) | CTSDBACE1BACE2KISS1R | |
| SCHEMBL23330932 | 0.91 | CTSD (0.56) | CTSDREN | |
| SCHEMBL23331576 | 0.90 | CDK4 (0.52) | CTSDKISS1RCTSBCTSKREN | |
| SCHEMBL23331564 | 0.90 | CTSD (0.51) | CTSDKISS1RCTSBCTSKREN | |
| SCHEMBL20714183 | 0.89 | KISS1R (0.55) | CTSDKISS1RPSEN1PSEN2APH1B | |
| SCHEMBL23331147 | 0.88 | KISS1R (0.54) | CTSDKISS1RPSEN1PSEN2APH1B | |
| SCHEMBL20714303 | 0.88 | KISS1R (0.54) | CTSDKISS1RPSEN1PSEN2APH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364275-B2 | Linear lipopeptide paenipeptins and methods of using the same | BIOVENTURES, LLC (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210128669-A1 | LINEAR LIPOPEPTIDE PAENIPEPTINS AND METHODS OF USING THE SAME | BIOVENTURES, LLC (US) | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364275-B2 | Linear lipopeptide paenipeptins and methods of using the same | NGLY1, VIP, CLPTM1 | CTSD 1815/4885BACE1 1709/4885BACE2 3380/4885 |
| US-20210128669-A1 | LINEAR LIPOPEPTIDE PAENIPEPTINS AND METHODS OF USING THE SAME | NGLY1, VIP, CLPTM1 | CTSD 1815/4885BACE1 1709/4885BACE2 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.